Syngene, an Indian CDMO, is to acquire Emergent’s Biosolutions Biologic’s plant in Baltimore, USA, for $36.5 million.

The facility is already set-up with multiple monoclonal antibody (mAb) manufacturing lines and will increase Syngene’s total single-use bioreactor capacity to 50,000 litres for the discovery, development and production of large molecules. The sale is expected to close in March with the plant able to accept new projects from clients in the second half of this year. As part of the agreement, Emergent will also have the opportunity to obtain future potential manufacturing capabilities from the Baltimore plant.